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Abstract The granulocytic differentiation of HL-60 cells
induced by all-trans retinoic acid was accompanied by a
progressive tyrosine phosphorylation of specific proteins in either
cells or isolated nuclei. Among these phosphoproteins, we
identified the Vav adaptor in whole cells as well as in the inner
nuclear compartment, where the increase in its tyrosine
phosphorylation level was more conspicuous. We also demon-
strated the differentiation-dependent association of nuclear
phosphorylated Vav to phospholipase C-Q1 and to the p85
regulatory subunit of phosphoinositide 3-kinase. The role of the
Vav/phospholipase C-Q1/phosphoinositide 3-kinase phosphopro-
tein complexes in the nuclei of HL-60 induced to differentiate
along the granulocytic lineage is discussed.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Growth factor receptors with intrinsic tyrosine kinase activ-
ity, upon activation, autophosphorylate their cytoplasmic
moiety on several tyrosine residues, which form distinct bind-
ing sites for SH2 domain-containing proteins. These activated
receptors can directly recruit a number of enzymes involved in
various signal transduction pathways, including components
of the lipid-dependent signaling pathways [1^3]. Other ago-
nists, which do not possess an intrinsic tyrosine kinase activ-
ity, are still able to activate non-receptor protein tyrosine
kinases (PTKs), inducing the tyrosine phosphorylation of sev-
eral substrates. A number of phosphotyrosine-containing pro-
teins, de¢ned as adaptor proteins, are recognized to play an
important role in linking the signal transduction emanating
from both activated receptors and non-receptor PTKs to lip-
id-dependent enzymes, such as phosphoinositide 3-kinase (PI
3-K) and phospholipase C-Q1 (PLC-Q1).
An adaptor protein known to bind to non-receptor PTKs is
the 95 kDa vav proto-oncogene product (Vav), which is highly
expressed in hematopoietic cells, and contains multiple struc-
tural motifs commonly found in intracellular signaling mole-
cules : SH2, SH3 and pleckstrin homology domains. It also
contains a region, highly homologous to the guanine nucleo-
tide exchange protein Dbl, termed Dbl homology or DH do-
main (for review, see [4]). The functional properties of the DH
domain of Vav in stimulating guanine nucleotide exchange on
Rac (GEF activity) are regulated by Lck-dependent phos-
phorylation on a speci¢c tyrosine residue [5,6].
The binding of the Vav SH2 domain to phosphorylated
PTKs is thought to serve for the recruitment of activated
kinases, which in turn can phosphorylate Vav [4]. Human
Vav protein contains 31 tyrosine residues with unknown func-
tional signi¢cance, except for Tyr-174, which is phosphoryl-
ated by Lck [4].
Other kinases appear to be responsible for tyrosine phos-
phorylation of Vav in di¡erent cell systems. The vav proto-
oncogene product participates in the signaling pathways acti-
vated by type I IFN receptor in U-266 and Daudi cells, by
interacting with the IFN receptor-associated Tyk-2 in vivo [7].
Vav might be a substrate for the kinase ZAP-70 in Jurkat T
cells stimulated by TCR, suggesting a role for the microtubule
in the signaling functions of these two proteins [8]. Vav was
then found to associate with and be tyrosine-phosphorylated
by activated JAK2 in vitro, in Epo-induced F-36P cells [9].
In vitro, tyrosine-phosphorylated Vav binds to a host of
SH2 domains, including those present in PLC-Q1 and in the
p85 regulatory subunit of PI 3-K.
In a recent work it was reported that both PtdIns(4,5)P2
and PtdIns(3,4,5)P3 interact with Vav, modulating the ability
of Lck to phosphorylate and activate Vav in response to mi-
togens. It has been proposed that the PH domain of Vav,
when complexed to PtdIns(4,5)P2, inhibits Vav GEF activity.
On the other hand, phosphorylation of Vav by Lck was en-
hanced in the presence of 3-phosphorylated lipids, suggesting
that activation of PI 3-K could serve to eliminate a Vav in-
hibitor and simultaneously produce activators of Vav activity
[10].
GAB1 represents a second example of docking protein,
which acquires the ability to interact with the SH2 domains
of Grb2, PLC-Q1 and PI 3-K upon tyrosine phosphorylation
[11]. A constitutive association between GAB1 and PI 3-K
was shown in cell lines overexpressing the epidermal growth
factor receptor [12]. GAB1 phosphorylation, followed by its
speci¢c interaction with several SH2 domain-containing
proteins, was also present as a consequence of treatment
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with nerve growth factor [13] and hepatocyte growth fac-
tor [14].
Although all-trans retinoic acid (ATRA) is known to act
through the RAR/RXR nuclear receptors, members of the
thyroid/steroid receptor superfamily of transcription factors
[15], we have previously demonstrated that the ATRA-in-
duced granulocytic di¡erentiation of the HL-60 cell line is
accompanied by a speci¢c nuclear pattern of expression and
activity of enzymes related to the phosphoinositide signaling
pathways [16]. We report here the presence of Vav adaptor
protein in nuclei from HL-60 cells and the association of
tyrosine-phosphorylated Vav with PI 3-K and PLC-Q1 in nu-
clei from di¡erentiated conditions. This suggests the existence
of a mechanism for recruiting and activating PI 3-K and PLC-
Q1 into the nucleus of cells di¡erentiating along the granulo-
cytic lineage.
2. Materials and methods
2.1. Cells and antibodies
HL-60 cells were obtained from the American Type Culture Col-
lection (ATCC CCL-240, Rockville, MD) and cultured in liquid sus-
pension in RPMI 1640 (Gibco Laboratories, Grand Island, NY) sup-
plemented with 10% fetal calf serum (Gibco) in a 94/6% air/CO2
atmosphere. Cells were maintained at an optimal cell density between
3U105/ml and 106/ml and treated with 1 WM ATRA (Sigma Chem-
icals, St. Louis, MO) for the indicated times. Cell di¡erentiation was
examined as previously reported [16,17].
Monoclonal anti-phosphotyrosine (P-Tyr) antibody was obtained
from Transduction Laboratories (PY20, Lexington, KY). Monoclonal
antibodies against p85 K and L subunits of PI 3-K, PLC-Q1 and Vav
and polyclonal antibody against GAB1 were purchased from Upstate
Biotechnology Inc. (Lake Placid, NY). Monoclonal anti-L-tubulin
antibody was from Sigma. Agarose-conjugated GST-p85 SH2-carbox-
yl (C)-terminal and SH2-amino (N)-terminal domains were from UBI.
Peroxidase-conjugated anti-rabbit and anti-mouse IgG (Sigma)
were used as secondary antibody, and the ¢nal detection was per-
formed using the ECL system (DuPont, NEN Research Products,
Boston, MA), according to the manufacturer’s instructions.
2.2. Preparation of cell lysates, nuclei and immunoprecipitates
Nuclei depleted of nuclear membranes were isolated following a
previously described procedure [16], in the presence of 0.5% Triton
X-100. All the puri¢cation bu¡ers contained 1 Wg/ml aprotinin,
1 Wg/ml leupeptin, 50 Wg/ml STI, 0.5 mM PMSF, 0.5 mM DTT and
1 mM Na3VO4 (all from Calbiochem, La Jolla, CA). Nuclear purity
was assessed by ultrastructural analysis and marker enzyme assays, as
previously reported [16,18]. As to the yield of the nuclear isolation,
from 1U106 cells were obtained, on average, 0.5U106 nuclei. In terms
of proteins, the content of 1U106 cells was 50 Wg, and 1U106 nuclei
was 10 Wg.
Cells and nuclei were lysed in a bu¡er containing 50 mM Tris-HCl,
pH 7.4; 1% Nonidet P-40; 0.25% sodium deoxycholate; 150 mM
NaCl; 1 mM EGTA, 1 mM PMSF; 1 Wg/ml each aprotinin, leupep-
tin; 1 mM Na3VO4 ; 1 mM NaF. After 20 min of incubation at 4‡C,
the insoluble materials were removed by centrifugation for 15 min at
14 000 rpm. Supernatant was incubated with the indicated antibodies
overnight at 4‡C and immunoprecipitated with protein A-Sepharose
(Pharmacia, Uppsala, Sweden). The immunoprecipitates were washed
four times with lysis bu¡er and resuspended in Laemmli’s SDS sample
bu¡er.
2.3. Immunochemical analysis
Total lysates and immunoprecipitates were separated on 7.5% poly-
acrylamide denaturing gels [19] and blotted to Trans-Blot nitrocellu-
lose membrane (Bio-Rad Laboratories, Richmond, CA). The blots
were then incubated with the antibodies, and revealed by the ECL
system (DuPont).
Each lane contained 50 Wg protein, obtained from 1U106 cells in
the case of total cell lysate, or from 5U106 membrane-depleted nuclei
in the case of nuclear lysate. For immunoprecipitation studies, 1 mg
of protein was employed in all cases, corresponding to 20U106 cells
or to 100U106 nuclei.
2.4. PI 3-kinase activity assay
The assays of PI 3-K catalytic activity on immunoprecipitates ob-
tained from total cells and nuclei were performed in the presence of
phosphatidylinositol (PI, in 10 mM HEPES, 1 mM EDTA, pH 7.5;
0.5 mg/ml ¢nal concentration). [Q-32P]ATP (10 WCi/sample) incorpo-
ration was achieved for 15 min at room temperature and the reaction
was stopped by addition of chloroform/methanol/HCl (200:100:0.75
v/v), followed by two washes with chloroform/methanol/HCl 0.6 N
(3:48:47 v/v). The lipid containing organic phase was resolved on
oxalate-coated thin-layer chromatography plates (Silica Gel 60,
Merck, Darmstadt, Germany) developed in isopropanol/acetic acid/
H2O (65:1:34 v/v). After autoradiography on Kodak X-Omat S ¢lms,
the spots were quanti¢ed by scintillation counting.
2.5. Statistical analysis
The results were expressed as mean þ S.D. of three or more experi-
ments performed in duplicate. Statistical analysis was performed using
the two-tailed Student’s t-test.
3. Results and discussion
For comparative analysis between cells and nuclei, Western
blots were performed by loading the same amount of protein
(50 Wg), obtained from 1U106 cells and 5U106 nuclei, respec-
tively.
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Fig. 1. Pattern of tyrosine-phosphorylated proteins in HL-60 cells
treated with ATRA. A: Purity of isolated nuclei was con¢rmed by
immunoblotting total lysates from control (3) and di¡erentiated (+)
conditions with the antibody against the cytoplasmic protein tubu-
lin. B: HL-60 cells and nuclei, stimulated (+) or not (3) with
ATRA for 96 h, were lysed and subjected to Western blot (WB)
analysis with anti-P-Tyr antibody. The positions of the proteins
showing an increase in the tyrosine phosphorylation levels upon
ATRA treatment are indicated with arrows, while the molecular
weights are indicated on the right. A representative of seven sepa-
rate experiments is shown.
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A 96 h treatment of HL-60 cells with 1036 M ATRA, which
induced terminal granulocytic di¡erentiation of most cells
[16,17], was accompanied by the tyrosine phosphorylation of
a number of proteins, in lysates obtained from either whole
cells or highly puri¢ed nuclei (Fig. 1). The proteins, whose
levels of tyrosine phosphorylation mostly increased after gran-
ulocytic di¡erentiation, migrated at about 38, 52, 70, 80, 100
and 150 kDa and 35, 48, 68, 100 and 150 kDa in cells and
isolated nuclei, respectively (Fig. 1). Of note, the only bands
showing a contemporaneous increase of tyrosine phosphoryl-
ation in both cells and nuclei were those at 100 and 150 kDa,
the increase of the former band being more prominent in
isolated nuclei.
To identify the nature of the 100 kDa phosphoprotein, total
lysates obtained from cells and nuclei were examined at di¡er-
ent time points of ATRA treatment, using antibodies against
two adaptor molecules, the 95 kDa Vav and GAB1. This
latter protein, despite the originally described molecular
weight of 116 kDa [11], is reported to migrate in the 100
kDa region (Upstate Biotechnology Catalog, Quality Control
Testing). As shown in Fig. 2A, the amount of the 100 kDa
phosphoprotein progressively increased during granulocytic
di¡erentiation in both cells and nuclei, starting from 48 h of
ATRA treatment onwards. However, the intensity of this
band reached higher levels in isolated nuclei than in total
cell lysates. When the membranes were probed with an anti-
Vav antibody, Vav protein was revealed in all samples, but it
showed an evident increase in nuclei obtained from di¡eren-
tiated cells (Fig. 2A). In contrast, when the membranes were
probed with an anti-GAB1 antibody, the presence of GAB1
was revealed in total cell lysates, but not in nuclei, and it did
not show signi¢cant variations during ATRA treatment.
In the next experiments, Vav protein was immunoprecipi-
tated from both cells (20U106) and nuclei (100U106) before
and after 96 h of ATRA treatment and initially revealed with
anti-P-Tyr antibody (Fig. 2B). A high level of tyrosine phos-
phorylation was observed in various bands (68, 75, 80, 100,
150 kDa), which were prominent in nuclei isolated from dif-
ferentiated cells. The anti-Vav antibody recognized a band,
comigrating with the 100 kDa phosphoprotein, which showed
a striking increase after ATRA treatment in both cells and
nuclei (Fig. 2B). It is remarkable that while the amount of
Vav protein, shown by Western blotting performed on either
whole lysates (Fig. 2A) or immunoprecipitates (Fig. 2B), was
lower in nuclei than in cells, its tyrosine phosphorylation level
was markedly higher in nuclei than in cells. These ¢ndings
highlight a preferential nuclear localization of tyrosine-phos-
phorylated Vav during the course of ATRA-induced granulo-
cytic di¡erentiation of HL-60 cells.
Since phosphorylated Vav is known to binds SH2-contain-
ing proteins [4] and we have previously demonstrated that
HL-60 granulocytic di¡erentiation is accompanied by a selec-
tive nuclear increase in both PLC-Q1 [16] and PI 3-K (Bertag-
nolo et al., in preparation), the Vav immunoprecipitates were
also probed with either anti-PLC-Q1 or anti-p85 antibodies
(Fig. 2B). Neither of these enzymes coimmunoprecipitated
with Vav in untreated cells and nuclei. On the other hand, a
signi¢cant amount of both enzymes coimmunoprecipitated
with Vav after granulocytic di¡erentiation (Fig. 2B). It is
also noteworthy that while the anti-PLC-Q1 recognized a
band comigrating with the 150 kDa phosphoprotein, the
anti-p85 did not recognize any of the phosphorylated bands
immunoprecipitated by the anti-Vav antibody. Work is in
progress to characterize the other tyrosine-phosphorylated
(75 and 80 kDA) bands, observed in isolated nuclei.
To further con¢rm the existence of protein-protein associ-
ation between Vav, PLC-Q1 and p85 we next performed
crossed immunoprecipitations with anti-PLC-Q1 (Fig. 3A)
and anti-p85 (Fig. 3B) antibodies. Probing the anti-PLC-Q1
immunoprecipitates with anti-P-Tyr revealed tyrosine phos-
phorylated bands of 70, 80, 100, 150 kDa, which increased
after ATRA treatment (Fig. 3A). Out of these four bands,
three (80, 100, 150 kDa) were detected in nuclei only upon
ATRA treatment. When probed with speci¢c antibodies, the
150 kDa band comigrated with PLC-Q1 (Fig. 3A), which in-
creased in the nucleus following treatment with ATRA.
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Fig. 2. Modulation of Vav protein and of its association to PLC-Q1 and p85 during ATRA-induced di¡erentiation. HL-60 cells were treated
with ATRA for the indicated times (hours). A: Whole lysates from cells and nuclei were subjected to immunoblot analysis with the anti-P-Tyr,
anti-Vav and anti-GAB1 antibodies, respectively. B: Cells and nuclei were immunoprecipitated (ip) with anti-Vav antibody and subjected to
WB analysis with anti-P-tyr antibody. Appropriate sections of the same membrane were then reprobed with the indicated antibodies. The posi-
tions of the tyrosine-phosphorylated proteins immunoprecipitated by anti-Vav antibody are indicated with arrows. In both panels, molecular
weights are indicated on the right. A representative of four to ¢ve separate experiments is shown.
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Vav protein was also clearly detectable in anti-PLC-Q1 im-
munoprecipitates of di¡erentiated cells and nuclei, further in-
dicating that the PLC-Q1/Vav association took place only
upon granulocytic di¡erentiation. On the other hand, no de-
tectable levels of GAB1 were present in anti-PLC-Q1 immuno-
precipitates, suggesting that Vav, but not GAB1, played a
prominent role as a docking molecule for PLC-Q1 in the di¡er-
ent subcellular compartments of HL-60. Additionally, the
anti-PLC-Q1 antibody coimmunoprecipitated p85 in both un-
treated and ATRA-treated cells, but the association of the
two enzymes increased signi¢cantly after ATRA treatment
(Fig. 3A). In contrast, the association between PLC-Q1 and
p85 in the nuclear compartment occurred only in di¡erenti-
ated conditions (Fig. 3A).
As shown in Fig. 3B, anti-p85 immunoprecipitated phos-
phoproteins of 70, 80, 100 and 150 kDa, and 100 and 150 kDa
in HL-60 cells and isolated nuclei, respectively. Once again,
these bands became more prominent (cells) or appear ex novo
(nuclei) only after ATRA-induced di¡erentiation. Of note,
also in this group of experiments, no phosphoproteins of 85
kDa could be shown, clearly indicating that phosphorylation
of p85 was not induced by ATRA. The amount of immuno-
precipitated p85 was constant in cells, while increasing in iso-
lated nuclei during granulocytic di¡erentiation. The 100 and
150 kDa phosphoproteins, present in both cells and nuclei,
comigrated with Vav and PLC-Q1, respectively (Fig. 3B). In
particular, immunoblotting with anti-Vav antibody demon-
strated that Vav copuri¢es in anti-p85 immunoprecipitates,
in both cells and nuclei, in a manner that correlated well
with ATRA treatment. In fact, no Vav protein could be de-
tected without di¡erentiative stimulus, clearly indicating that
also the interaction between p85 and Vav was induced by the
di¡erentiative process.
Probing the p85 immunoprecipitates against GAB1 showed
the presence of this adaptor in cells, but not in nuclei, con-
¢rming the absence of GAB1 from nuclei as shown in Fig. 2A.
Moreover, the amount of GAB1 coimmunoprecipitated by
p85 was constant and, therefore, independent of granulocytic
di¡erentiation (Fig. 3B).
As PI 3-K holoenzyme is composed by a regulatory (p85)
and a catalytic (p110) subunit [20], a further set of experi-
ments was directed to evaluate the catalytic activity of PI
3-K in di¡erent immunoprecipitation experiments. The in
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Fig. 4. In vitro association of Vav and GAB1 with the N- and C-
terminal SH2 domains of p85. Lysates from cells and nuclei treated
(+) or not (3) with ATRA for 96 h were incubated with agarose-
conjugated GST-p85 SH2 N-terminal or SH2 C-terminal. The sam-
ples were immunoblotted (WB) with the indicated antibodies. The
positions of 97.4 phosphoprotein, Vav and GAB1 are indicated by
arrows. A representative of three separate experiments is shown.
Fig. 3. Association of PLC-Q1 and p85 with Vav. Lysates from cells and nuclei at di¡erent times (hours) of ATRA treatment were immunopre-
cipitated (ip) with (A) anti-PLC Q1 and (B) anti-p85 antibodies and immunoblotted (WB) with anti-P-Tyr antibody. Appropriate sections of the
same membrane were then reprobed with the indicated antibodies. The positions of the relevant tyrosine-phosphorylated proteins associated to
PLC Q1 and p85 are indicated with arrows. In both panels, molecular weights are indicated on the right. C: Immunoprecipitates (ip) with the
indicated antibodies from cells and nuclei were subjected to an in vitro PI 3-K assay, using PI as substrate. OR = origin, PIP = phophatidyl-
inositol 3-phosphate. A representative of three to six separate experiments is shown.
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vitro PI 3-K activity in the anti-p85 immunoprecipitates
showed a signi¢cant (P6 0.01) increase in isolated nuclei,
but not in cells, upon granulocytic di¡erentiation (Fig. 3C).
These data correlated well with the modi¢cations in the
amount of p85 immunoprecipitated from untreated and
ATRA-treated HL-60 cells and nuclei (Fig. 3B). According
to previous results, PI 3-K activity in anti-P-Tyr and anti-
Vav immunoprecipitates was also signi¢cantly (P6 0.01)
higher in nuclei isolated after ATRA treatment than in nuclei
isolated from untreated cells (Fig. 3C).
The association of p85 with the tyrosine-phosphorylated
Vav suggests that this binding might be mediated through
the SH2 domains of p85 [4]. To evaluate whether the two
SH2 domains of p85 [20] were responsible for its interaction
with Vav, in the next experiments cells and nuclei were ad-
sorbed on GST-fusion N-terminal and C-terminal p85-SH2
proteins. In control cells, ATRA treatment increased the
Vav binding to both N- and C-terminal SH2s, with most of
Vav being copuri¢ed on C-terminal p85 SH2 (Fig. 4). In con-
trast, in isolated nuclei, it was the SH2 N-terminal that in-
creased its association with tyrosine-phosphorylated proteins
in di¡erentiated conditions (Fig. 4). We also probed the bind-
ing of the other 100 kDa phosphoprotein GAB1 and we
showed that, in total cell lysates, the GAB1 protein was prev-
alently associated with SH2 N-terminal, without signi¢cant
changes due to di¡erentiation (Fig. 4). Although we have
not addressed the reason for the di¡erential ability of Vav
to bind the SH2 domains of p85 in whole cells and nuclei,
this might be due to a distinct pattern of tyrosine phosphoryl-
ation of cytosolic vs. nuclear Vav, or it may depend on steric
hindrance in cytosolic Vav due to the binding of other pro-
teins to its phosphotyrosines.
In this study, we have demonstrated for the ¢rst time the
presence of Vav/PLC-Q1/PI 3-K proteins including complexes
in the nucleus of di¡erentiating HL-60 cells. Since PLC-Q1
antibody immunoprecipitates p85, the presence of a complex
including at least these three proteins is likely. Although we
have previously shown that PLC-Q1 can strongly associate
with the nuclear matrix (nucleoskeleton) of the HL-60 cell
line [16], and a study is in progress to characterize the pres-
ence and function of PI 3-K in the inner nuclear compart-
ment, the demonstration that Vav functions as an adaptor
protein for these enzymes also at the nuclear level was unex-
pected and represents a novel ¢nding. Since Vav is the only
one of the Vav/PLC-Q1/PI 3-K proteins to possess a nuclear
localization sequence [4], it is possible that Vav is directly
involved in the nuclear transportation of PLC-Q and PI 3-K.
Several possibilities can be envisioned to explain the pro-
gressive accumulation of Vav adaptor protein in the nucleus
of the HL-60 cell line induced to di¡erentiate by ATRA.
Some studies have already reported the presence of Vav in
the nuclear compartment [21,22], and recent observations
may revive interest in the role of Vav for the regulation of
gene expression and other nuclear functions [23^25]. It has
also been demonstrated that Vav can associate with several
cytoskeletal proteins, including tubulin, zyxin and polymer-
ized actin [4]. Although the meaning of the Vav association
with proteins of the cytoskeleton is not known, it is possible
that Vav translocates into the nucleus via components of the
cytoskeleton. Since we and other groups of investigators have
previously shown that the nuclear matrix contains all the in-
ositol lipid substrates for PLC-Q1 and PI 3-K [26^28], the
presence of Vav inside the nucleus might suggest an essential
role in targeting PLC-Q1 and PI 3-K enzymes to their relevant
nuclear substrates.
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